Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd versus T-DM1 in high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy
jRCT2061200033Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Trastuzumab deruxtecan with Trastuzumab emtansine (2 arms). Primary endpoint: Invasive disease-free survival. Started Dec 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecantrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2061200033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200033.